INTRODUCTION
============

Schizophrenia is a complex psychiatric disorder characterized by a marked thinking disturbance and is also a devastating disorder with a high degree of morbidity.[@B1] Twin, adoption, and family studies have implicated that schizophrenia is one of genetic disorders with high heritability.[@B2],[@B3] Several lines of evidences suggest that genetic factors contribute to the susceptibility of schizophrenia. [@B4],[@B5] Recently, many genetic studies have been reported the relationship between schizophrenia and single nucleotide polymorphisms (SNPs) of candidate genes and/or copy number variants and susceptible loci through the genome-wide association study.[@B6]-[@B8]

The dopamine receptor D2 (DRD2) is a G protein-coupled receptor inhibiting adenylyl cyclase activity. This receptor is located on postsynaptic dopaminergic neurons involved in reward-mediating mesocorticolimbic pathways.[@B9] DRD2 consists of 2 isoforms, D2S (shot isoform) and D2L (long isoform). D2L has an additional 29 amino acids in the third intracellular loop, compared to D2S. D2L acts at postsynaptic sites and D2S plays a role in presynaptic autoreceptor functions. The pharmacological effects of haloperidol are absent in D2L deficient mice, suggesting D2L is targeted by haloperidol.[@B10] The DRD2 signaling plays a crucial role in the physiopathologic conditions such as locomotion and drug abuse. It is well-known that DRD2 may be related to the susceptibility of schizophrenia. Antipsychotic drugs block postsynaptic DRD2. Postmortem studies have reported that DRD2 density is increased in the caudate, putamen, and nucleus accumbens of schizophrenia patients.[@B11] Drugs increasing dopaminergic activity such as levodopa and bromocriptine aggravate schizophrenic symptoms.[@B12]-[@B15] Although DRD2 is implicated in the pathogenesis of schizophrenia, the genetic determinants still remain.

In this study, we investigated whether SNPs of the DRD2 gene are associated with schizophrenia in a Korean population.

METHODS
=======

Study Subjects
--------------

Schizophrenia patients were enrolled among participants who visited at the departments of neuropsychiatry in the East-West Neomedical Center and Kyung Hee Medical Center (Seoul, Korea). A total of 197 Korean schizophrenia patients and 370 healthy subjects were recruited. The schizophrenia group (n=197) comprised 113 males and 84 female, and the mean age of schizophrenia patients was 42.2±10.8 (mean±standard deviation) years. The control group (n=370) consisted of 187 males and 183 females. The mean age of controls was 44.3±6.3 years. Patients were diagnosed as schizophrenia by well-trained psychiatrists according to the Diagnostic and Statistical Manual of Mental Disorders (fourth edition) using available information from interviews and clinical records. Control subjects were recruited among individuals assessed as mentally healthy through a general health examination program. Subjects with neurological diseases and any severe diseases were excluded. This study was carried out in accordance with the guidelines of the Helsinki Declaration and approved by the Ethics Review Committee of Medical Research Institute, Kyung Hee University Medical Center, Seoul, Republic of Korea. Written informed consent was obtained from each subject.

Genotyping
----------

In this study, we focused on intronic SNPs (iSNPs) in the intron 1 region of DRD2: (1) we wanted to find out new SNPs related to schizophrenia susceptibility; (2) the methylation of CpG islands has been identified in the intron 1 of DRD2.[@B16] We searched DRD2 SNPs in the NCBI websites ([www.ensembl.org](http://www.ensembl.org), [www.broad.mit.edu/mpg/tagger](http://www.broad.mit.edu/mpg/tagger), [www.hapmap.org](http://www.hapmap.org), and [www.ncbi.nlm.nih.gov/](http://www.ncbi.nlm.nih.gov/) SNP, BUILD135). SNPs with \<5% minor allele frequency, \<10% heterozygosity, and monomorphic genotype in Asian populations were excluded. Finally, we selected four iSNPs (rs4648317, rs7131056, rs4936270, and rs1076562) ([Fig. 1](#F1){ref-type="fig"}). Peripheral blood samples were collected in EDTA or heparin tubes from each subject. DNA was isolated using the DNA Isolation Kit for Cells and Tissues (Roche, Indianapolis, IN, USA) and the genotypes of four SNPs were determined by direct sequencing (MACROGEN, Seoul, Korea). Polymerase chain reactions (PCRs) using the sense and antisense primers of each SNP were conducted ([Table 1](#T1){ref-type="table"}). The PCR products were sequenced by an ABI PRISM 3730XL analyzer (PE Applied Biosystems, Foster City, CA, USA) and SeqManII software (DNASTAR, Madison, WI, USA) was used to analyze the sequencing data.

Statistical Analysis
--------------------

SNPStats (<http://bioinfo.iconcologia.net/index.php?module=Snpstats>) and SNPAnalyzer Pro (ISTECH, Goyang, Korea) were used to calculate odds ratios (ORs), 95% confidence intervals (CIs), and *p* values adjusting for age and gender as covariables. Multiple logistic regression models were employed to analyze genetic data: codominant1 (major allele homozygotes vs. heterozygotes), codominant2 (major allele homozygotes vs. minor allele homozygotes), dominant (major allele homozygotes vs. heterozygotes+minor allele homozygotes), recessive (major allele homozygotes+heterozygotes vs. minor allele homozygotes), overdominant (major allele homozygotes+minor allele homozygotes vs. heterozygotes), and log-additive (major allele homozygotes vs. heterozygotes vs. minor allele homozygotes). The linkage disequilibrium (LD) block and haplotypes were evaluated using Haploview 4.2 (Daly Lab, Cambridge, MA, USA). Bonferroni\'s correction was applied by multiplying the *p* values by the number of SNPs. Hardy-Weinberg equilibrium (HWE) was calculated using the chi-squared test. Statistical significance was evaluated using SPSS ver. 15.0 (SPSS Inc., Chicago, IL, USA) and set at *p*\<0.05.

RESULTS
=======

Genotype Analysis
-----------------

The genotype and allele frequencies of the four examined SNPs are shown in [Table 2](#T2){ref-type="table"}. Four iSNPs (rs4648317, rs7131056, rs4936270, and rs1076562) of DRD2 were in HWE in the schizophrenia and control groups, respectively (*p*\>0.05, data not shown). Three SNPs (rs4648317, rs7131056, and rs1076562) were not associated with schizophrenia. However, the genotype frequency of rs4936270 was associated with the development of schizophrenia (*p*=0.0007, OR=1.71, 95% CI=1.16-2.52 in the codominant1 model; *p*=0.011, OR=1.63, 95% CI=1.12-2.37 in the dominant model; *p*=0.035, OR=1.41, 95% CI=1.03-1.95 in the log-additive model). The allele frequency of rs4936270 was also associated with the development of schizophrenia (*p*=0.024, OR=1.45, 95% CI=1.05-1.98). The C/T genotype and C allele frequencies of rs4936270 was higher in the schizophrenia group (34.7 and 20.3%) than in the control group (23.5 and 15.0%). After Bonferroni\'s correction, the genotype distribution of rs4936270 showed statistical difference between schizophrenia and controls (*p^c^*=0.0028 in the codominant1 model; *p^c^*=0.044 in the dominant model). These results suggest that rs4936270 may be a risk factor for schizophrenia development.

Linkage Disequilibrium and Haplotypes
-------------------------------------

In order to evaluate the LD block and haplotypes of the four tested SNPs, we used Haploview 4.2 program. In [Fig. 2](#F2){ref-type="fig"}, a LD block was made among rs4648317, rs7131056, and rs4936270 SNPs in the control group (rs4648317 and rs7131056, D\'=1, r^2^=0.528; rs7131056 and rs4936270, D\'=1, r^2^=0.227; rs4648317 and rs4936270, D\'=1, r^2^=0.120). We also investigated the association between the haplotypes and schizophrenia. As shown in [Table 3](#T3){ref-type="table"}, frequency in four haplotypes showed \>0.1. The distribution of TCC, CAC, CAT, CCC haplotypes was 0.400, 0.275, 0.166, and 0.157, respectively. The CAT haplotype was weakly associated with the development of schizophrenia (*p*=0.039). In addition, the genotype frequencies of the four examined SNPs (rs4648317, rs1076562, rs4936270, and rs7131056) were compared to those of European and other East Asian populations. The genotype frequencies of three SNPs (rs4648317, rs1076562, and rs7131056) were similar to those of Japanese, whereas the genotype frequencies of rs4936270 were similar to those of European ([Table 4](#T4){ref-type="table"}).

Sample Power
------------

The power of the sample size was estimated using a genetic power calculator (<http://pngu.mgh.harvard.edu/~purcell/gpc>). When the conditions of the sample power (α=0.05, risk=two-fold, the number of case=80% power) were employed, we had 0.9143 for rs4648317 (n=138), 0.9251 for rs7131056 (n=133), 0.9184 for rs4936270 (n=136), and 0.8906 for rs1076562 (n=151). Therefore, our case-control study was sufficiently powerful to study a positive correlation.

DISCUSSION
==========

A number of studies have been published the relationship between DRD2 SNPs and schizophrenia. Betcheva et al.[@B17] demonstrated that rs6277 (C957T, Pro319Pro) was significantly associated with schizophrenia after the replication study using independent sample set (OR=1.76, p=0.001). Fan et al.[@B18] reported that T allele of rs6277 (Pro319Pro) was weakly associated with schizophrenia (OR=1.58, 95% CI=1.03-2.43, *p*=0.034), while the genotype and allele frequencies of rs6275 (C939T, His313His) were not associated with schizophrenia in Chinese Han population. They suggest that rs6277 T allele may play a role in the genetic vulnerability for schizophrenia. A missense SNP rs1801028 (Ser311Cys) was reported to have an effect on risk for schizophrenia.[@B19] In contrast, Glatt and co-workers[@B20] did not find a significant effect of rs1801028 for association of schizophrenia in a family-based study. A study using in Southern Indian population found an association between the genotype distribution of rs6275 and schizophrenia (χ^2^=8.91, *p*=0.011).[@B21] The rs2734839 iSNP was reported to have an association with schizophrenia with late onset age.[@B22] Lee et al.[@B23] showed that rs1799978 (promoter SNP), rs4245149 (iSNP), and rs4620755 (iSNP) were not associated with schizophrenia in Korean population.

Focusing on the our tested SNPs, rs4648317 was associated with better performance on the stop task in the drug free condition and lower scores on the impulsivity subscale.[@B24] Laucht et al.[@B25] found that carriers of the T allele of rs4648317 were higher rates of current smoking and scored higher on nicotine dependence than their allelic counterparts. Völter et al.[@B26] reported that rs4648317 was related to prepulse inhibition of the acoustic startle response in the Munich sample, but not in the London sample. A Finnish population-based cohort showed an association between rs7131056 and social phobia (*p*=0.0084).[@B27] Todt et al.[@B28] reported that rs7131056 was associated with migraine with aura in a large German migraine with aura case-control sample (uncorrected allelic *p*=0.0018, OR=1.28). However, this correlation did not conform in 2,937 British control individuals. The rs7131056 iSNP was reported to have initial significant association with nicotine dependence in European Americans, but not after correction for multiple testing, indicating a weak association of rs7131056 with nicotine dependence.[@B29] Xing et al.[@B30] reported that rs1076562 did not show any association with the response to risperidone in Chinese patients with schizophrenia.

A famous SNP as known as TaqI DRD2 (rs1800497) is located within exon 8 of the adjacent gene, ankyrin repeat and kinase domain containing 1 (ANKK1). Therefore, we did not discuss about rs1800497 studies in this study.

In conclusion, we investigated whether four iSNPs (rs4648317, rs7131056, rs4936270, and rs1076562) of DRD2 are associated with schizophrenia in Korean population. We found that the genotype distribution of rs4936270 was associated with schizophrenia (*p^c^*=0.0028 in the codominant1 model; *p^c^*=0.044 in the dominant model) and the CAT haplotype was different between schizophrenia and controls (*p*=0.039). These results suggest that rs4936270 of DRD2 may be associated with the susceptibility of schizophrenia. To confirm our results, replication studies of a large number of cases and/or additional studies of other DRD2 SNPs will be required.
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Primer sequences of DRD2 SNPs
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DRD2, dopamine receptor D2; SNP, singe nucleotide polymorphism; bp, base pair.
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Genotype and allele frequencies of DRD2 SNPs in control subjects and schizophrenia patients
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DRD2, dopamine receptor D2; SNP, singe nucleotide polymorphism; SPR, schizophrenia; OR, odds ratio; CI, confidence interval.

The *p* values were calculated from logistic regression analysis adjusting age and sex. Bold number indicates significant association.
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Haplotype analysis of DRD2 SNPs in control subjects and schizophrenia patients

![](cpn-10-88-i003)

DRD2, dopamine receptor D2; SNP, singe nucleotide polymorphism; SPR, schizophrenia.

Haplotypes comprised of rs4648317, rs7131056, and rs4936270. Bold number indicates significant association.
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Genotype and allele frequencies of DRD2 SNPs in European and Asian populations
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DRD2, dopamine receptor D2; SNP, singe nucleotide polymorphism; CEU, Utah residents with Northern and Western European ancestry from the CEPH collection; CCB, Han Chinese in Beijing, China; JPT, Japanese in Tokyo, Japan.

^\*^Control subjects in this study (<http://www.ncbi.nlm.nih.gov/projects/SNP>).
